Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.6.1.2 (
alanine aminotransferase
)
26,722
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cefminox (
CMNX
, MT-141) was given intravenously to 20 children with the following acute bacterial infections; 10 cases of bronchopneumonia, 4 cases of urinary tract infection, 2 cases of staphylococcal scalded skin syndrome, each 1 case of acute pharyngitis, acute tonsillitis, purulent cervical lymphadenitis and acute tonsillitis, and pleuritis. Good clinical responses were obtained in 18 patients out of 20 patients and bacteriological effectiveness in 13 strains out of 14 strains. No side effect was observed except for 1 case with diarrhea and 1 case with slight elevation of GOT and
GPT
. From the above clinical results, it is apparent that
CMNX
is a useful antibiotic for treating pediatric patients with various kinds of bacterial infections.
...
PMID:[Clinical experience with cefminox in the pediatric field]. 387 40
Fundamental and clinical trials were carried out with cefminox (
CMNX
, MT-141) in pediatric infections. Results were as follows. The mean serum concentrations of
CMNX
following intravenous injection of 10, 20 and 40 mg/kg were 73.1, 112.5 and 181.4 micrograms/ml at 15 minutes after injection, respectively. The serum half-life times were 1.37, 1.20 and 1.53 hours, respectively. Average recovery rates in the urine until 6 hours from the start of injection were 91.4, 59.4 and 85.8%, respectively. The antimicrobial activity of
CMNX
against clinically isolated organisms was measured;
CMNX
was more active than CMZ and CEZ against H. influenzae.
CMNX
was equal to or more active than CMZ and CEZ against E. coli.
CMNX
was administered clinically to 32 pediatric patients with various infections; 19-pneumonia, 5-bronchopneumonia, 3-bronchitis and 5-pyelonephritis. Overall efficacy rate was 93.8%. Slight elevation of S-GOT and S-
GPT
was observed in 2 patients. No other serious side effect was observed.
...
PMID:[Clinical evaluation of cefminox in pediatric field]. 389 3